These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21039620)

  • 21. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examining advocacy and comprehensive cancer control.
    Selig WK; Jenkins KL; Reynolds SL; Benson D; Daven M
    Cancer Causes Control; 2005 Oct; 16 Suppl 1():61-8. PubMed ID: 16208575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of human parasitic diseases: Context and overview.
    Molyneux DH
    Adv Parasitol; 2006; 61():1-45. PubMed ID: 16735161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of a change in Medicare reimbursement policy and HEDIS measures on stage at diagnosis among Medicare HMO and fee-for-service female breast cancer patients.
    Habermann EB; Virnig BA; Riley GF; Baxter NN
    Med Care; 2007 Aug; 45(8):761-6. PubMed ID: 17667310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 26. Health outcomes and managed care: discussing the hidden issues.
    Chin MH
    Am J Manag Care; 1997 May; 3(5):756-62. PubMed ID: 10169537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Policy and advocacy in the quest for effective translational breast care research.
    La Fargue MM
    Breast; 2010 Aug; 19(4):303-6. PubMed ID: 20399093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ever-changing face of breast advocacy.
    Wagner JA
    Breast; 2010 Aug; 19(4):280-3. PubMed ID: 20392642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies.
    Van Herck P; Annemans L; Sermeus W; Ramaekers D
    PLoS One; 2013; 8(10):e78662. PubMed ID: 24205290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
    Hughes D; Williams-Jones B
    Healthc Policy; 2013 Aug; 9(1):52-64. PubMed ID: 23968674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based policy-making: the implications of globally-applicable research for context-specific problem-solving in developing countries.
    Behague D; Tawiah C; Rosato M; Some T; Morrison J
    Soc Sci Med; 2009 Nov; 69(10):1539-46. PubMed ID: 19781839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer patient advocacy: new opportunities for treatment advances.
    Quale DZ; Droller MJ
    Urol Oncol; 2007; 25(4):351-2. PubMed ID: 17628308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in getting workforce research in nursing used for decision-making in policy and practice: a Canadian perspective.
    O'Brien-Pallas L; Hayes L
    J Clin Nurs; 2008 Dec; 17(24):3338-46. PubMed ID: 19146593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of market-based 'reform' on cultural values in health care.
    Curtin LL
    Semin Nurse Manag; 1999 Dec; 7(4):198-202. PubMed ID: 11013589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The patient as a policy factor: a historical case study of the consumer/survivor movement in mental health.
    Tomes N
    Health Aff (Millwood); 2006; 25(3):720-9. PubMed ID: 16684736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective.
    Bines J; Eniu A
    Cancer; 2008 Oct; 113(8 Suppl):2353-8. PubMed ID: 18837028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The debate about the funding of Herceptin: a case study of 'countervailing powers'.
    Gabe J; Chamberlain K; Norris P; Dew K; Madden H; Hodgetts D
    Soc Sci Med; 2012 Dec; 75(12):2353-61. PubMed ID: 23036988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.